Is Regencell Bioscience Stock a Good Investment?
Regencell Bioscience Investment Advice | RGC |
- Examine Regencell Bioscience's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Regencell Bioscience's leadership team and their track record. Good management can help Regencell Bioscience navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Regencell Bioscience's business and its evolving consumer preferences.
- Compare Regencell Bioscience's performance and market position to its competitors. Analyze how Regencell Bioscience is positioned in terms of product offerings, innovation, and market share.
- Check if Regencell Bioscience pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Regencell Bioscience's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Regencell Bioscience Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Regencell Bioscience Holdings is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Regencell Bioscience Stock
Researching Regencell Bioscience's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 89.0% of the company outstanding shares are owned by corporate insiders. The book value of Regencell Bioscience was at this time reported as 0.92. The company has Price/Earnings To Growth (PEG) ratio of 2.15. Regencell Bioscience recorded a loss per share of 0.45. The entity last dividend was issued on the 1st of December 2017.
To determine if Regencell Bioscience is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Regencell Bioscience's research are outlined below:
| Regencell Bioscience generated a negative expected return over the last 90 days | |
| Regencell Bioscience has high historical volatility and very poor performance | |
| Reported Net Loss for the year was (6.06 M) with profit before taxes, overhead, and interest of 0. | |
| Regencell Bioscience Holdings has about 59.41 K in cash with (4.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 89.0% of the company outstanding shares are owned by corporate insiders |
Regencell Bioscience Quarterly Cost Of Revenue |
|
Regencell Bioscience uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Regencell Bioscience Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Regencell Bioscience's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of January 2024 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View |
Regencell Bioscience Analyst Ratings
Regencell Bioscience's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Regencell Bioscience stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Regencell Bioscience's financials, market performance, and future outlook by experienced professionals. Regencell Bioscience's historical ratings below, therefore, can serve as a valuable tool for investors.Know Regencell Bioscience's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Regencell Bioscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regencell Bioscience Holdings backward and forwards among themselves. Regencell Bioscience's institutional investor refers to the entity that pools money to purchase Regencell Bioscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2023-12-31 | 16.1 K | Blackrock Inc | 2023-12-31 | 238 | Qube Research & Technologies | 2023-12-31 | 13.0 | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 0.0 | Tower Research Capital Llc | 2023-12-31 | 0.0 |
Regencell Bioscience's market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 77.82 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Regencell Bioscience's market, we take the total number of its shares issued and multiply it by Regencell Bioscience's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Regencell Bioscience's profitablity analysis
Regencell Bioscience's profitability indicators refer to fundamental financial ratios that showcase Regencell Bioscience's ability to generate income relative to its revenue or operating costs. If, let's say, Regencell Bioscience is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Regencell Bioscience's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Regencell Bioscience's profitability requires more research than a typical breakdown of Regencell Bioscience's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.05 | 0.05 | |
| Return On Capital Employed | 0.12 | 0.12 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | (0.13) | (0.14) |
Determining Regencell Bioscience's profitability involves analyzing its financial statements and using various financial metrics to determine if Regencell Bioscience is a good buy. For example, gross profit margin measures Regencell Bioscience's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Regencell Bioscience's profitability and make more informed investment decisions.
The data published in Regencell Bioscience's official financial statements usually reflect Regencell Bioscience's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Regencell Bioscience. For example, before you start analyzing numbers published by Regencell accountants, it's critical to develop an understanding of what Regencell Bioscience's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Regencell Bioscience's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Regencell Bioscience's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Regencell Bioscience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Regencell Bioscience Holdings. Please utilize our Beneish M Score to check the likelihood of Regencell Bioscience's management manipulating its earnings.
Evaluate Regencell Bioscience's management efficiency
Regencell Bioscience has Return on Asset of (0.2559) % which means that on every $100 spent on assets, it lost $0.2559. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4171) %, meaning that it generated no profit with money invested by stockholders. Regencell Bioscience's management efficiency ratios could be used to measure how well Regencell Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. At present, Regencell Bioscience's Return On Capital Employed is projected to slightly decrease based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.04, whereas Return On Equity is forecasted to decline to (0.14). At present, Regencell Bioscience's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Return On Tangible Assets is expected to grow to 0.05, whereas Total Assets are forecasted to decline to about 10.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (5.47) | (5.75) | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | (7.96) | (8.36) | |
| Enterprise Value Over EBITDA | 8.06 | 8.47 | |
| Price Book Value Ratio | (1.92) | (2.01) | |
| Enterprise Value Multiple | 8.06 | 8.47 | |
| Price Fair Value | (1.92) | (2.01) | |
| Enterprise Value | 3.2 B | 3.3 B |
The analysis of Regencell Bioscience's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Regencell Bioscience's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Regencell Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta (0.35) |
Basic technical analysis of Regencell Stock
As of the 8th of May, Regencell Bioscience holds the Variance of 85.36, risk adjusted performance of 0.0076, and Coefficient Of Variation of (36,281). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Regencell Bioscience, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to analyze and collect data for thirteen technical drivers for Regencell Bioscience, which can be compared to its competitors. Please check Regencell Bioscience standard deviation, treynor ratio, as well as the relationship between the Treynor Ratio and potential upside to decide if Regencell Bioscience is priced some-what accurately, providing market reflects its current price of 5.98 per share. Given that Regencell Bioscience has information ratio of (0.01), we recommend you to check out Regencell Bioscience's recent market performance to make sure the company can sustain itself at a future point.Regencell Bioscience's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regencell Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regencell Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regencell Bioscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Brandow Peter B 3 days ago Disposition of 1564 shares by Brandow Peter B of Regencell Bioscience at 22.97 subject to Rule 16b-3 | ||
Amy Miles over a month ago Disposition of 33006 shares by Amy Miles of Regencell Bioscience at 21.58 subject to Rule 16b-3 | ||
Peter Brandow over a month ago Disposition of 1265 shares by Peter Brandow of Regencell Bioscience at 22.87 subject to Rule 16b-3 |
Understand Regencell Bioscience's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Regencell Bioscience's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0076 | |||
| Market Risk Adjusted Performance | 0.0603 | |||
| Mean Deviation | 5.99 | |||
| Coefficient Of Variation | (36,281) | |||
| Standard Deviation | 9.24 | |||
| Variance | 85.36 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | 0.0106 | |||
| Total Risk Alpha | (1.00) | |||
| Treynor Ratio | 0.0503 | |||
| Maximum Drawdown | 47.56 | |||
| Value At Risk | (13.08) | |||
| Potential Upside | 23.15 | |||
| Skewness | 1.28 | |||
| Kurtosis | 2.55 |
| Risk Adjusted Performance | 0.0076 | |||
| Market Risk Adjusted Performance | 0.0603 | |||
| Mean Deviation | 5.99 | |||
| Coefficient Of Variation | (36,281) | |||
| Standard Deviation | 9.24 | |||
| Variance | 85.36 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | 0.0106 | |||
| Total Risk Alpha | (1.00) | |||
| Treynor Ratio | 0.0503 | |||
| Maximum Drawdown | 47.56 | |||
| Value At Risk | (13.08) | |||
| Potential Upside | 23.15 | |||
| Skewness | 1.28 | |||
| Kurtosis | 2.55 |
Consider Regencell Bioscience's intraday indicators
Regencell Bioscience intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Regencell Bioscience stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.12 | |||
| Day Median Price | 5.98 | |||
| Day Typical Price | 5.98 | |||
| Price Action Indicator | 0.33 | |||
| Period Momentum Indicator | 0.65 | |||
| Relative Strength Index | 69.86 |
Regencell Bioscience Corporate Filings
6K | 2nd of January 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 27th of October 2023 Other Reports | ViewVerify |
Regencell Stock media impact
Far too much social signal, news, headlines, and media speculation about Regencell Bioscience that are available to investors today. That information is available publicly through Regencell media outlets and privately through word of mouth or via Regencell internal channels. However, regardless of the origin, that massive amount of Regencell data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Regencell Bioscience news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Regencell Bioscience relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Regencell Bioscience's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Regencell Bioscience alpha.
Regencell Bioscience Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Regencell Bioscience can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Regencell Bioscience without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Financial Widgets Now
Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
| All Next | Launch Module |
Regencell Bioscience Corporate Management
Elected by the shareholders, the Regencell Bioscience's board of directors comprises two types of representatives: Regencell Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regencell. The board's role is to monitor Regencell Bioscience's management team and ensure that shareholders' interests are well served. Regencell Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regencell Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wai Chung | COO Officer | Profile | |
| Tien Chau | Executive Officer | Profile | |
| Michelle Chan | Financial Controller | Profile | |
| YatPui Au | Chief Officer | Profile | |
| YatGai Au | Chairman Founder | Profile | |
| Antonia Assang | Senior Management | Profile |
How to buy Regencell Stock?
To provide specific investment advice or recommendations on Regencell Bioscience Holdings stock, we recommend investors consider the following general factors when evaluating Regencell Bioscience Holdings. This will help you to make an informed decision on whether to include Regencell Bioscience in one of your diversified portfolios:- Examine Regencell Bioscience's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Regencell Bioscience's leadership team and their track record. Good management can help Regencell Bioscience navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Regencell Bioscience's business and its evolving consumer preferences.
- Compare Regencell Bioscience's performance and market position to its competitors. Analyze how Regencell Bioscience is positioned in terms of product offerings, innovation, and market share.
- Check if Regencell Bioscience pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Regencell Bioscience's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Regencell Bioscience Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Regencell Bioscience Holdings is a good investment.
Already Invested in Regencell Bioscience Holdings?
The danger of trading Regencell Bioscience Holdings is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Regencell Bioscience is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Regencell Bioscience. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Regencell Bioscience is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Regencell Bioscience information on this page should be used as a complementary analysis to other Regencell Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Regencell Stock analysis
When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Regencell Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Return On Assets (0.26) | Return On Equity (0.42) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Regencell Bioscience's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.